Scarica l'app Stockscreener
4.29
5.41%
0.22
Dopo l'orario di chiusura:
4.32
0.03
+0.70%
Precedente Chiudi:
$4.07
Aprire:
$4
Volume 24 ore:
341.97K
Relative Volume:
1.32
Capitalizzazione di mercato:
$58.66M
Reddito:
-
Utile/perdita netta:
$-59.52M
Rapporto P/E:
-0.9739
EPS:
-4.4049
Flusso di cassa netto:
$-51.87M
1 W Prestazione:
-6.54%
1M Prestazione:
+51.59%
6M Prestazione:
+53.21%
1 anno Prestazione:
+3.87%
Intervallo 1D:
$4.00
$4.45
Intervallo di 1 settimana:
$3.58
$4.45
Portata 52W:
$1.70
$4.75
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.29 | 58.66M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
Breakouts Watch: Can OnKure Therapeutics Inc deliver consistent EPS growthDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure (OKUR) CEO Nicholas Saccomano awarded 330,000 stock options - Stock Titan
OnKure (OKUR) CFO granted 110,000 stock options at $4.07 - Stock Titan
OnKure Therapeutics (OKUR) awards 110,000 options to Chief Scientific Officer - Stock Titan
OnKure (OKUR) grants CMO 110,000 stock options at $4.07 strike - Stock Titan
OnKure (OKUR) director receives 15,300 stock options at $4.14 strike price - Stock Titan
OnKure Therapeutics (OKUR) director Liam Ratcliffe submits Form 3 insider report - Stock Titan
Acorn funds and Anders Hove disclose stakes in OnKure (NASDAQ: OKUR) up to 9.5% - Stock Titan
Leerink cuts OnKure stock price target on strategic shift By Investing.com - ca.investing.com
Leerink cuts OnKure stock price target on strategic shift - investing.com
OnKure Announces $150M Private Placement and Board Changes - tipranks.com
OnKure elects Dr. Liam Ratcliffe as director under Lead Investor designation - TradingView
OnKure (NASDAQ: OKUR) secures $150M private placement and refocuses PI3Kα pipeline - Stock Titan
Panic Selling: Whats the profit margin of OnKure Therapeutics IncTake Profit & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com
OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade
OnKure Therapeutics Inc. Sees Variable Performance Amid Market Fluctuations - timothysykes.com
OnKure to sell $150M in stock to fund drug development - dailycamera.com
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
Oppenheimer reiterates OnKure stock rating on pipeline shift By Investing.com - Investing.com India
Oppenheimer reiterates OnKure stock rating on pipeline shift - Investing.com
Aug Wrap: Is OnKure Therapeutics Inc in a bullish channelWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
OnKure Therapeutics, Inc. announced that it expects to receive $149.999126 million in funding from a group of investors - MarketScreener
OnKure Therapeutics Stock Fluctuates With Market Shifts - StocksToTrade
Unprecedented Gains: OKUR Clinches Pivotal Industry Deal - timothysykes.com
Onkure Therapeutics to advance next-generation PI3Kα pan-mutant programs - BioWorld MedTech
OnKure raises $150M to advance breast cancer programs - Investing.com
OnKure raises $150M to advance breast cancer programs By Investing.com - Investing.com UK
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Onkure Therapeutics Announces Appointment of Liam Ratcliffe to Board of Directors - MarketScreener
OnKure Therapeutics CEO Saccomano sells $357 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March - marketbeat.com
OnKure Therapeutics CFO Leverone sells $1.2k in shares - Investing.com UK
OnKure Therapeutics CFO Leverone sells $1.2k in shares By Investing.com - au.investing.com
OnKure Therapeutics CEO Saccomano sells $357 in stock - Investing.com
OnKure (OKUR) CEO makes small 86-share sale to cover RSU taxes - Stock Titan
OnKure Therapeutics (OKUR) CFO sells 301 shares to cover RSU tax withholding - Stock Titan
If You Invested $1,000 in OnKure Therapeutics (OKUR) - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-19 04:03:55 - baoquankhu1.vn
OnKure reports nearly $60M cash on hand as drug trials continue - BizWest
HC Wainwright Has Positive Forecast for OKUR Q1 Earnings - MarketBeat
OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright - Defense World
OnKure Therapeutics (OKUR): HC Wainwright & Co. Adjusts Price Ta - GuruFocus
H.C. Wainwright cuts OnKure stock price target to $27 on funding By Investing.com - Investing.com South Africa
H.C. Wainwright cuts OnKure stock price target to $27 on funding - Investing.com Australia
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):